Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.
The studies, conducted in both Type 2 diabetic (T2D) non-human primates (NHPs) and mice, provide the first in vivo proof-of-concept that the therapy can "rejuvenate" exhausted beta cells and restore normal glucose control.
GPX-002 utilizes an adeno-associated virus (AAV) vector to deliver two key transcription factors, Pdx1 and MafA, directly to the pancreas.
In Type 2 diabetes, where beta cells become "exhausted" and fail to produce sufficient insulin, this genetic reprogramming aims to restore their natural function.
While Genprex previously showed that GPX-002 could convert alpha cells into "beta-like" cells in Type 1 diabetes, these new results confirm its potential to address the much larger T2D market.